to identical HA regions, with only minor variations in the magnitude of their responses in spite of differences in their age and exposure to influenza A viruses.
In order to extend our initial observations and to explore in detail epitope selection by HLA class II, we have now examined the HA-specific repertoires of six unrelated adults, aged 27-60 years, selected because they expressed identical HLA-DR alleles (HLA DRB1*0701, *1501). Five of the six donors also expressed the same HLA-DRW (DRB4*01, *501) and HLA-DQ alleles (DQA*0101/4, *0501 and DQB1*02, *0601/ 2). Short-term CD4 ϩ T cell lines were selected with full length HA A/Beijing/32/92 (H3N2), prior to and 3 months following vaccination with a trivalent subunit influenza vaccine containing HA A/Beijing/32/92. Epitope recognition was examined using a panel of 118 synthetic peptides 16 amino acids in length and overlapping by 11 residues, that spanned the entire HA A/Beijing/32/92 molecule.
Because murine studies using panels of overlapping synthetic peptides spanning the sequence of staphylococcal nuclease have reported a strong association between the strength of CD4 ϩ T cell peptide recognition and peptide binding affinity for MHC class II (6) (7) (8) , we then employed a competition assay, using biotinylated CLIP peptide, to estimate the relative binding affinities of the HA peptides for purified HLA-DR. This allowed a preliminary analysis of the importance of peptide-HLA class II relative binding affinity in the development of a hierarchy of immunodominance for human CD4 ϩ T cell responses to HA.
Methods

Subjects and vaccination
CD4 ϩ T cell responses by six unrelated healthy Caucasian adult volunteers, aged between 27 and 60 years, to HA from influenza A/Beijing/32/92 (H3N2) were investigated prior to and 3-4 months following influenza subunit vaccination, although the pre-vaccination line from donor C was lost in culture. Subjects D, E and F were originally found by chance to share HLA class II types. Donors A-C were specifically chosen because they were known to have a very closely matched HLA class II type to donors D, E and F (see below). HLA-DR and DQ typing was performed using the 'phototyping' method (employing sequence specific primer PCR) (9) . Donors A-C, E and F expressed identical HLA-DRB1*1501, *0701, DRB4*01, DRB5*01, DQA1*0101/4, *0501 and DQB1*02, *0601/2 alleles. Donor D differed only in that he expressed DQB1*0303 rather than DQB1*02, this is associated with the non-expression of the donor's DRB4*01 allele (10) . The following HLA-DP types were obtained by sequencing: donor B, HLA-DP*0301, *0402; donor C HLA-DP*0201, *0401; and donor F, HLA-DP*0401, *0402. Donors HLA class I types, as determined by phototyping, were as follows: donor A, HLA-A3, B7,13 Cw4,6; donor B, HLA-A1,2, B62,64, Cw8,304; donor C, HLA-A30, 31 
Peptides and antigens
Highly purified full-length HA derived from influenza A/Beijing/ 32/92 (H3N2) was a gift from Dr R Brands. HA from influenza A/Aichi/68 (the original H3N2 human influenza strain) was the gift of Dr J. Skehel (National Institute for Medical Research, Mill Hill, London, UK) and was obtained by bromelain cleavage of the recombinant influenza A virus X-31. It contained trace contaminants of other influenza proteins (11) .
A series of 16 amino acid peptides overlapping by 11 residues was derived from the nucleotide sequence of the HA1 subunit of HA A/Beijing/32/92 and the HA2 subunit of the closely related A/Hong Kong/90 virus, as no sequence information was available on the HA2 subunit of A/Beijing/32/ 92. Unpublished sequence information from both viruses was kindly supplied by Dr N. Cox (CDC, Atlanta, GA). The amino acid sequence and method of synthesis of the peptides has been previously described, and they showed no significant mitogenic activity on a CD4 ϩ T cell line specific for Mycobacterium tuberculosis soluble extract (4). In the text peptides are numbered according to their N-and C-terminal residues, and peptide pools are numbered by the N-terminal residue of their N-terminal peptide and the C-terminal residue of their C-terminal peptide.
CD4 ϩ T cell lines
Short-term CD4 ϩ T cell lines were selected using purified fulllength HA A/Beijing/32/92 as previously described (4) . In brief, short-term CD4 ϩ T cell lines were obtained by stimulating fresh peripheral blood mononuclear cells (PBMC) (5ϫ10 6 / well) with purified HA A/Beijing/32/92 0.05 µg/ml, in RPMI 1640 supplemented with 5% heat inactivated human AB ϩ serum (Sigma, Poole, UK), 2 mM glutamine, 100 IU/l of penicillin-streptomycin at 37°C, 5% CO 2 . At 7 and 14 days T cells were re-stimulated with equal numbers of autologous irradiated (3000 rad) PBMC (freshly thawed, from liquid nitrogen storage) pre-pulsed with 0.01-0.05 µg/ml of HA A/ Beijing/32/92, and cultured in complete medium at a density of 1ϫ10 6 T cells/well. Then 10% Lymphocult (Biotest Folex, Frankfurt, Germany) as a source of IL-2 was added on days 8, 11, 15 and 18. By 21 days of culture, short-term CD4 ϩ T cell lines selected as above are Ͼ90% CD3 ϩ , 78-88% CD4 ϩ and 2-10% CD8 ϩ (4).
Analysis of T cell specificities using overlapping HA peptides At 14 and 21 days of culture autologous, irradiated (3000 rad) PBMC (4ϫ10 4 cells/0.2 ml well) were incubated with whole HA (HA A/Beijing/32/92, 0.01-0.1 µg/ml) or HA peptide pools (five peptides at an individual concentration of 10 µg/ ml) and cultured with 4ϫ10 4 Further HLA restriction studies were conducted on a 2 week HA/Beijing/32/92-specific CD4 ϩ short-term T cell line derived from donor D as described above. HA peptide proliferation was examined as described above with one modification: 4ϫ10 4 (14) as previously described (15) . In brief a 10 g cell pellet was lysed in PBS containing 2% CHAPS (v/v), leupeptin (2 µg/ ml), pepstatin (2 µg/ml) and 5 mM EDTA. Cell lysates were centrifuged at 100,000 g for 90 min at 4°C then loaded onto an L-243 affinity column. The column was washed extensively and then material eluted with 0.05 % diethylamine/150 mM NaCl/0.1% CHAPS, pH 11.5. Eluate was concentrated on a Centricon-10 column (Amicon).
Peptide binding studies
An invariant chain fragment containing the CLIP peptide (LPKPPKPVSKMRMATPLLMQ) [Ii-(97-120)] was biotinylated using biotinamidocaproate N-hydroxysuccinamide ester (Sigma). Binding of peptides to DR molecules was measured by their ability to inhibit the binding of the biotinylated CLIP peptide as previously described (14) . Briefly, 0.1 µg of HLA-DR was incubated with biotinylated CLIP peptide (0.02 µg) with or without inhibitor peptide (10, 1 and 0.1 µg) at 37°C for 24 h at pH 5. Solutions were neutralized with Tris-HCl (pH 7.5) before transfer to wells pre-coated with L-243 antibody. Binding of biotinylated peptide was detected with ExtrAvidinhorseradish peroxidase conjugate (Sigma) and developed with o-phenylenediamine. The OD at 492 nm was measured using an ELISA plate reader and the concentration of each HA peptide which caused a 50% inhibition in biotinylated CLIP peptide binding calculated (IC 50 ) using standard methods. When CD4 ϩ T cell responses to individual HA peptides within the dominant peptide pools were examined (Fig. 2) , every CD4 ϩ T cell line was found to recognize identical HA peptides or pairs of overlapping peptides, with the exception of donor E, whose responses to pools 407-442 and 456-488 could not be localized. Furthermore, where responses localized to pairs of overlapping peptides, the relative strength of responses to each individual peptide was the same. Thus the response to peptide 87-102 was stronger than the response to peptide 92-107, the response to peptide 232-247 was stronger than the response to peptide 228-243, and the responses to peptides 463-478 and 468-483 were similar to each other in magnitude (with the exception of donor E). These peptides represent regions of HA which have been free of extensive drift mutation since the emergence of the H3N2 subtype. Though the CD4 ϩ T cell response of these donors is principally focused on conserved regions of HA, we cannot exclude the possibility that donors A, C and G have mounted minor but significant (Ͼ5 times the geometric mean background) responses to neutralizing antibody sites A, B, and/or D which are represented by peptides in pool 137-171.
Results
HA and HA peptide recognition
HLA class II restriction of T cell responses to intact HA and HA peptides
In order to examine HLA restriction of CD4 ϩ T cell responses to HA, PBMC from two donors with partial HLA class II matches were used as APC (Fig. 3) . The 'DR0701' donor expressed HLA-DRB1*0101, DRB1*0701, DRB4*01, DQB1*05 and DQB1*02. The 'DR15' donor expressed HLA-DRB1*0408, DRB1*1501, DRB4*01, DRB5*01, DQB1*0301 and DQB1*0601/0602. When PBMC from the 'DR0701' donor were used as APC, strong T cell proliferative responses were seen to peptides 87-102, 232-247, 463-478 and 468-493, indicating that these responses were primarily restricted to either HLA-DRB1*0701, DRB4*01, DQB1*02 or HLA DP (see below). When PBMC from the 'DR1501 donor' were used as APC, T cell responses were seen to peptides 232-247 and 417-432.
CD4 ϩ T cell recognition of peptides 87-102, 232-247, 463-478 and 468-493 is unlikely to be primarily DQB1*02 restricted because donor D, who does not express DQB1*02, had a very similar peptide recognition pattern to the other donors. These responses are also unlikely to be DRB4*01 restricted. First, both the 'DR0701' donor and the 'DR1501' donor expressed DRB4*01, yet strong responses to peptides 87-102, 232-247, 463-478 and 468-493 were only seen when PBMC from the 'DR0701' donor were used as APC; secondly, donor D, who does not express DRB4*01 (10) has a very similar HA peptide recognition pattern to the other donors; and, finally, we have previously examined five other DRB4*01 positive donors, none of whom recognized peptides 87-102 and 232-247 (4, 5) . CD4 ϩ T cell recognition of peptides 87-102, 232-247, 463-478 and 468-493 is also unlikely to be primarily HLA-DP restricted because donors B, C and F express different HLA-DP alleles (HLA-DP*0301,*0402, HLA-DP*0201,*0401, and HLA-DP*0401,*0402 respectively). This indicated that the majority of CD4 ϩ T cell responses to HA in these donors were HLA-DR0701 restricted.
In order to test this hypothesis we repeated the HA peptide proliferation studies using a murine fibroblast line expressing HLA-DRB1*0701 (DAP.DR7.0701) as APC (Fig. 4) . CD4 ϩ T cell responses were seen to peptides 232-247, 417-432, 463-478, 468-483 and 508-523 indicating that these responses were DR0701 restricted. No T cell proliferative response was seen to peptide 87-102, the reason for the loss of recognition of this peptide is not clear but might reflect differences in antigen processing between murine fibroblasts and human PBMC (see Discussion).
HLA-DR0701 peptide binding studies
We were interested to examine whether the observed CD4 ϩ T cell HA epitope recognition pattern was simply a consequence of dominant HA peptides having high binding affinities for HLA-DR0701, leading to their preferential recognition to the exclusion of other potential epitopes. The relative binding strength of the 118 HA peptides for purified DR0701 was estimated in a competition assay using biotinylated invariant chain peptide (Ii) (Fig. 4) . Fifty seven of the peptides inhibited Ii binding with an IC 50 Ͻ 100 µM. Of these nine had an IC 50 ϭ 1.0 µM and 31 had IC 50 ϭ 10 µM (Table 1) . The HA peptides recognized by CD4 ϩ T cells in the context of DR0701 either had detectable binding to this molecule or in the case of peptide 468-483 overlapped (by 11 residues) a peptide which was recognized in the context of DR0701 and had a relative binding strength of Ͻ10 µM for this molecule. The strongest proliferative response was associated with a peptide with IC 50 ϭ 1 µM (peptide 232-247). However, there was no direct relationship between relative binding strength and magnitude of response; the second strongest response was associated with two overlapping peptides, one with IC 50 ϭ 8.1 µM (peptide 463-478) and the other with IC 50 Ͼ 100 µM (peptide 468-483), and the third strongest was associated with two peptides with IC 50 ϭ 20 µM. Only five peptides representing the HA2 subunit (residues 329-550) had IC 50 Ͻ 100 µgM, with the highest relative strength belonging to peptide 508-523 (2.1 µM). In addition the peptide with the highest relative strength for DR0701 (peptide 192-207) was not recognized by CD4 ϩ T cells, despite its ability to induce proliferation in the context of DR0101 [ (4, 5) , and C. Gelder and B. Askonas, unpublished observations]. Relative binding strength of a panel of frequently recognized HA peptides for common DR alleles In order to extend our observations on the relationship between HA peptide relative binding strength and CD4 ϩ T cell recognition we investigated the binding strength of 13 HA peptides which we had previously found to be recognized in association with other HLA class II alleles (4, 5) . The results of this study are shown in Fig. 5 . Because of the varying strength of CLIP for individual HLA-DR molecules (16) , results for different HLA class II molecules cannot be directly compared. HA peptide binding was a prerequisite for CD4 ϩ T cell recognition. However, peptide binding to HLA-DR did not automatically result in CD4 ϩ T cell recognition. In particular, peptide 232-247, which elicits strong responses in the context of DR0701, also had measurable binding to DR0101 and to DR1302, and we have not observed CD4 ϩ T cell recognition of peptide 232-247 in the context of these HLA molecules [ (4, 5) , and C. Gelder and B. Askonas, unpublished observations].
Comparison of observed pattern of HLA-DR0701 HA peptide binding to a previously described DR0701 peptide binding motif
The observed pattern of HA peptide binding matched was compared with a reported HLA-DR0701 peptide binding motif (P1 ϭ FILVY, P4ϭ NST) derived from pool sequencing of peptides eluted from DR0701 (17) . Though some of the HA peptides can be aligned with this motif, a new motif P1 I, L, V, (W or Y) and P9 V, I, L, (Y or F) fitted the observed pattern of HA peptide binding more exactly, and there appears to be a preference (though not an absolute requirement) for hydrophobic residues at P2 and P7, polar residues at P4 and P6, and small residues at P5 (Table 1) . This putative motif suggests that though the P1 and P9 pockets are important for peptide selection, other residues in the peptide binding groove interact with DR0701 and that the final peptide affinity for DR0701 is the combination of several pocket specificities. Interestingly the few peptides which did not fit the P9 requirements have suitable residues located at P10 or P8, which might reflect some flexibility in peptide binding.
Discussion
In this report we have shown that HA-specific short-term CD4 ϩ T cell lines generated from six unrelated DR0701, 1501 (4, 5) . Using DAP.DR7 cells as APC (a murine cell line which expresses HLA-DR0701) CD4 ϩ T cell recognition of four of the selected peptides (peptides 232-247, 417-432, 463-478 and 468-493) was shown to be HLA-DR0701 restricted and other evidence was provided that recognition of the fifth peptide (peptide 87-102) might also be DR0701 restricted.
Using biotinylated CLIP peptide, purified DR0701 and a competition assay, the relationship between CD4 ϩ T cell recognition and relative binding affinity of the HA peptides for purified HLA-DR0701 was explored and found to be complex. The relative binding affinity of the five principally recognized HA peptides varied from 0.2 (peptide 232-247) to Ͼ100 µM (peptide 468-483). Furthermore, the majority of peptides which bound to DR0701, including the peptide with the highest relative affinity for DR0701 (peptide 192-207, 0.09 µM), were not recognized by CD4 ϩ T cells. The finding of peptide binding in the absence of a CD4 ϩ T cell response was not unique to DR0701, as peptide 232-247 bound to both HLA-DR0101 and 1302 but was not recognized in the context of either HLA molecule. Our finding that in adults CD4 ϩ T cells principally focus on conserved HA regions contrasts the murine CD4 ϩ T cell responses to HA following nasal H3 influenza A infection where both CBA (18, 19) and BALB/c (18, 20, 21) mice principally recognize HA epitopes closely associated with the highly variable antibody neutralizing sites rather than conserved regions of the molecule (22) . The murine response has also been reported to be diverse with T cell clones from individual syngeneic mice recognizing different HA epitopes and clear MHC-restricted patterns of response only emerginge once the responses of several mice are combined (23) . These apparent species differences may reflect differences in previous exposure to influenza. The mice were examined after a single in vivo infection, whereas our adult human donors will have been repeatedly exposed to different strains influenza A virus (see below).
CD4 ϩ T cell epitope selection is dependent on many factors, which include antigen processing (24, 25) , the ability of processed peptide to bind to MHC class II molecules (26) , competition amongst peptides for MHC binding (27, 28) and the presence of an appropriate repertoire of TCR (29) . There are therefore several possible explanations for our finding that the relative strength of HA peptide DR0701 binding does not directly relate to the observed CD4 ϩ T cell repertoire. Some HA peptides may not elicit T cell responses because their natural equivalents do not emerge from antigen processing in vivo. As It is also possible that failure of some of the HA peptides to be recognized might be due to the absence of CD4 ϩ T cell expressing appropriate TCR, due to regions of sequence identity between the HA peptides and self proteins. Such cross-reactivity has been demonstrated in a murine CTL clone specific for HA residues 210-219 of influenza A/Japan/57 (H2N2), which also recognized the variable region of a myeloma V H chain (30) . We therefore searched the Swiss Protein Database for regions of sequence identity between the HA peptides which bound to DR0701 but were not recognized and self proteins. Interestingly we found 79% homology between the nine core residues of peptide 192-207, as predicted by our putative HLA-DR0701 peptide binding motif, and human galactosidase 2 (data not shown).
Antibody binding to an antigen has also been reported to modulate CD4 ϩ T cell responses (31, 32) . Several HA peptides which were not recognized by CD4 ϩ T cells, including peptide 192-208 which displayed the highest relative binding strength for DR0701, were located in or close to antibody neutralizing sites. The neutralizing antibody response to HA is variable between individuals and is largely influenced by exposure history (33) . As the pre-vaccination exposure of these six donors varied, a more diverse pattern of CD4 ϩ T cell HA recognition might be expected, if significant antibody modulation of CD4 ϩ T cell recognition had occurred in this system. Viral drift mutation may also have influenced CD4 ϩ T cell HA epitope recognition. The majority of peptides with an IC 50 for DR0701 of Ͻ 10 µM which were not recognized by the short-term CD4 ϩ T cell lines represent regions of HA that have undergone drift mutations since the emergence of the H3N2 subtype in 1968 (see Table 1 ; N. Cox, CDC, Atlanta, GA, pers. commun.). These mutations were frequently nonconservative in nature. Six peptides representing conserved regions of HA (peptides 100-115, 105-120, 282-297, 354-369, 363-378 and 513-528) were not recognized in the context of DR0701 despite relative binding affinities for DR0701 of Ͻ10 µM. We have previously observed responses to two of these peptides (100-115 and 105-120) in the context of DR0101 [ (4, 5) , and C. Gelder and B. Askonas, unpublished observations]. In contrast, the HA peptides which induced CD4 ϩ T cell responses in the context of DR0701 contained a maximum of two highly conservative drift mutations and did not represent glycosylated regions of the molecule (see below). Thus the observed DR0701-associated HA epitope recognition pattern seen in these adult donors may have emerged as a consequence of repeated exposure to influenza A strains, differing in HA, boosting recognition of conserved regions of the molecule. Such selection of T cells specific for conserved HA epitopes would explain the apparent species differences in HA recognition described above. In order to test this hypothesis it will be important to examine CD4 ϩ T cell recognition of HA by infants and children following their first exposure to influenza.
Several of the peptides which bound to DR0701 but which were not recognized, represent HA regions with potential glycosylation sites (glycosylation motif is Asn-X-Ser/Thr, peptides 20-35, 30-45, 156-171, 236-251, 238-253, 243-258, 273-288 and 282-297) (N. Cox, CDC, Atlanta, GA, pers. commun.). Glycosylation of HA has been shown in murine systems to abrogate CD4 ϩ T cell recognition of HA (34) and therefore may account for the absence of CD4 ϩ T cell recognition of our synthetic peptides despite their high relative binding affinities for DR0701. We have only rarely seen significant T cell recognition ( (4, 5) , and C. Gelder and B. Askonas, unpublished observations]. It will be important to examine whether human CD4 ϩ T cells are able to recognize glycosylated synthetic peptides representing these regions.
Finally these results illustrate the difficulty in accurately predicting CD4 ϩ T cell epitopes in viral antigens on the basis of peptide binding studies alone.
In conclusion we have demonstrated the precise control HLA class II exerts over CD4 ϩ T cell HA epitope selection in unrelated adults. Immunodominance appears not to be directly related to the relative strength of HA peptide-HLA class II binding, and thus reflects complex interactions between antigen processing, intracellular competition for HLA binding, TCR repertoires and repeated exposure to different strains of influenza A viruses.
